Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression — Stella

Home/Bipolar Depression/

View on ClinicalTrials.gov

Recruiting

Back to Bipolar Depression trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Canada

Toronto Western Hospital - University Health Network, Toronto, Ontario

Key details

Phase

Early testing

Sponsor

University Health Network, Toronto

Collaborators

Centre for Addiction and Mental Health

Enrollment target

~30 participants

Started

October 2024

Primary completion

September 2026

Age range

18 Years – 65 Years

Last updated October 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.